PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.

ABSTRACT:

SUBMITTER: Burger J 

PROVIDER: S-EPMC9431502 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature